Clinical Characteristics, Diagnosis, and Outcomes of Moxifloxacin-Associated Bilateral Acute Iris Transillumination
Abstract
To explore the clinical characteristics of moxifloxacin-associated bilateral acute iris transillumination (BAIT) and provide references for diagnosis and treatment. The clinical reports of moxifloxacin-associated BAIT were collected before August 31, 2025, and the clinical data were extracted for retrospective analysis. A total of 40 patients were included, with a median age of 53 (range 26, 77), including 28 (70.0%) women. The median occurrence time of BAIT was 14 days (rang 0.2, 60). Patients may present with photophobia (75.0%), decreased vision (67.5%), ocular pain (50.0%), and high intraocular pressure (32.5%). Ophthalmic examination shows iris transillumination. After the patients discontinued moxifloxacin and received topical steroids and anti-glaucoma treatment, the symptoms of most patients improved, while transillumination remained. The patient developed ocular symptoms such as photophobia, ocular pain and decreased vision during the use of moxifloxacin, which requires further examination. If iris transillumination, ocular hypertension and acute pigment dispersion of the iris pigment epithelium are found during ophthalmic examination, the possibility of BAIT should be considered.
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.